308430
CellBion Co., Ltd. engages in the research and development of radiopharmaceutical products. Its clinical stage pipeline includes 177Lu-PSMA-DGUL, indicated for prostate cancer radiotherapy, currently under Phase 2 clinical stage; 225Ac-Antibody, indicated for multiple cancer types, currently under pre-clinical stage; 225Ac-DGUL, indicated for prostate cancer radiotherapy, currently under pre-clin… Read more
308430 (308430) - Total Assets
Latest total assets as of March 2025: ₩33.84 Billion KRW
Based on the latest financial reports, 308430 (308430) holds total assets worth ₩33.84 Billion KRW as of March 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
308430 - Total Assets Trend (2022–2024)
This chart illustrates how 308430’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
308430 - Asset Composition Analysis
Current Asset Composition (December 2024)
308430's total assets of ₩33.84 Billion consist of 91.8% current assets and 8.2% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩1.21 Billion | 0.0% |
| Accounts Receivable | ₩471.36 Million | 1.4% |
| Inventory | ₩483.63 Million | 1.4% |
| Property, Plant & Equipment | ₩955.78 Million | 2.8% |
| Intangible Assets | ₩634.80 Million | 1.8% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2022–2024)
This chart illustrates how 308430's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: 308430's current assets represent 91.8% of total assets in 2024, an increase from 75.4% in 2022.
- Cash Position: Cash and equivalents constituted 0.0% of total assets in 2024, down from 0.0% in 2022.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, a decrease from 6.0% in 2022.
- Asset Diversification: The largest asset category is cash and equivalents at 0.0% of total assets.
308430 Competitors by Total Assets
Key competitors of 308430 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
308430 - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - 308430 generates 0.07x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - 308430 is currently not profitable relative to its asset base.
308430 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 23.82 | 3.62 | 3.62 |
| Quick Ratio | 23.41 | 3.25 | 3.25 |
| Cash Ratio | 1.10 | 1.30 | 1.30 |
| Working Capital | ₩30.06 Billion | ₩ 4.58 Billion | ₩ 4.58 Billion |
308430 - Advanced Valuation Insights
This section examines the relationship between 308430's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 14.15 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 203.3% |
| Total Assets | ₩34.41 Billion |
| Market Capitalization | $153.64 Million USD |
Valuation Analysis
Below Book Valuation: The market values 308430's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: 308430's assets grew by 203.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for 308430 (2022–2024)
The table below shows the annual total assets of 308430 from 2022 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩34.41 Billion | +203.27% |
| 2023-12-31 | ₩11.35 Billion | +13.04% |
| 2022-12-31 | ₩10.04 Billion | -- |